NF-κB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells

Prostate

Volumn 66, Issue 11, 2006, Pages 1223-1234

  Armstrong, Kelly ^a   Robson, Craig N ^a   Leung, Hing Y ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

FGF8; HDAC; PI 3K; Prostate; Trichostatin A

Indexed keywords

FIBROBLAST GROWTH FACTOR 8; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; DNA; ENZYME INHIBITOR; FGF8 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYBRID PROTEIN; HYDROXAMIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; RELA PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA; TRICHOSTATIN A;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GRADING; CANCER SURVIVAL; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ACETYLATION; BINDING SITE; CHEMISTRY; CHROMATIN; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACETYLATION; BASE SEQUENCE; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN; DNA; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTOR 8; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOSORBENT TECHNIQUES; MALE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 33746836575     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20376     Document Type: Article

References (54)

1. Isaacs W, De Marzo A, Nelson WC. Focus on prostate cancer. Cancer Cell 2002;2(2):113-116.
2. Tanaka T, Saito H, Matsuki N. Basic fibroblast growth factor modulates synaptic transmission in cultured rat hippocampal neurons. Brain Res 1996;723(1-2):190-195.
3. Payson RA, Wu J, Liu Y, Chiu IM. The human FGAg gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells. Oncogene 1996;13(1):47-53.
4. Ohuchi H, Yoshioka IH, Tanaka A, Kawakami Y, Nohno T, Noji S. Involvement of androgen-ind need growth factor (FGF-8) gene in mouse embryogenesis and morphogenesis. Biochem Biophys Res Commun 1994;204(2):882-888.
5. Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL. FCF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene 2001;20(22):2791 -2804.
6. Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, Lakkakorpi IT, Harkonen PL. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001;61(10):4229-4237.
7. Chosh AK, Shankar DB, Shackleford GM, Wu K, T'Ang A, Miller CJ, Zheng J, Roy-Burman P. Molecular cloning and characterization of human FGF8 alternative messenger RNA forms. Cell Growth Differ 1996;7(10):1425-1434.
8. Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller CJ, Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000;60(23):6730-6736.
9. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M, Fukayama M. High frequency of fibroblast growth factor (FCF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 1998;58(10):2053-2056.
10. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FCF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999;18(17):2755-2761.
11. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 2002;21(33)5069-5080.
12. Gemel J, Jacobsen C, MacArthur CA. Fibroblast growth factor-8 expression is regulated by intronic engrailed and Pbxl-binding sites. J Biol Chem 1999;274(9):6020-6026.
13. Aggarwal BB. Nuclear factor-kappa B: The enemy within. Cancer Cell 2004;6(3):203-208.
14. Nakshatri H, Bhat-Nakshatri P, Martin DA, Coulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17(7):3629-3639.
15. Casparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV. The role of 1KK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115(Pt 1):141-151.
16. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA. Mutual transeriptional interference between RelA and androgen receptor. J Biol Chem 1996;271(39):24151-24156.
17. Quivy V, Van Lint C. Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol 2004;68(6):1221-1229.
18. Greene WC, Chen LF. Regulation of NF-kappaB action by reversible acetylation. Novartis Found Symp 2004;259:208-217; discussion 218-225.
19. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Janne OA, Muratoglu S, Avantaggiati ML, Pestell RG. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003;23(23):8563-8575.
20. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101(5):1241-1246.
21. Leu TH, Yeh HH, Huang CC, Chuang YC, Su SL, Maa MC. Participation of p97Eps8 in Src-mediated transformation. J Biol Chem 2004;279(11):9875-9881.
22. Camarero N, Nadnl A, Barrero MJ, Haro D, Marrero PF. Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site. Nucleic Acids Res 2003;31(6):1693-1703.
23. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21 WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000;19(50):5712-5719.
24. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002;97(3):290-296.
25. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, Kim KW. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 2003;300(1):241-246.
26. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 2002;22(3):1497-1504.
27. Yoshida M, Beppu T. Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A. Exp Cell Res 1988;177(1):122-131.
28. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor upregulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003;63(12):3069-3072.
29. Tsurutani J, Soda H, Oka M, Suenaga M, Doi S, Nakamura Y, Nakatomi K, Shiozawa K, Amada YY, Kamihira S, Kohno S. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 2003;104(2):238-242.
30. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase 1 trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8(3):718-728.
31. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9(10 Pt 1):3578-3588.
32. Zelivianski S, Glowacki R, Lin MF. Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site. Nucleic Acids Res 2004;32(12):3566-3580.
33. Schmid JA, Birbach A, Hofer-Warbinek R, Pengg M, Burner U, Furtmuller PG, Binder BR, de Martin R. Dynamics of NF kappa B and lkappa Balpha studied with green fluorescent protein (GFP) fusion proteins. Investigation of GFP-p65 binding to DNa by fluorescence resonance energy transfer. J Biol Chem 2000;275(22):17035-17042.
34. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, Robson CN. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 1999;274(25):17599-17604.
35. Wang Q, Stamp GW, Powell S, Abel P, Laniado M, Mahony C, Lalani EN, Waxman J. Correlation between androgen receptor expression and FGF8 mRNA levels in patients with prostate cancer and benign prostatic hypertrophy. J Clin Pathol 1999;52(1):29-34.
36. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DF, Leung HY. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003;22(9):1381-1389.
37. Braunstein M, Rose AB, Holmes SG, Allis CD, Broach JR. Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes Dev 1993;7(4):592-604.
38. Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and isupregulated inandrogen-independent prostate cancer. Mol Cell Biol 2002;22(8):2862-2870.
39. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of nngiogenesis, invasion, and metastasis. Oncogene 2001;20(31):4188-4197.
40. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001;21(20):7065- 7077.
41. Kiernan R, Bres V, Ng KW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278(4):2758-2766.
42. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18(18):2195-2224.
43. Kim YK, Han JW, Woo YN, Chun JK, Yoo JY, Cho EJ, Hong S, Lee HY, Lee YW, Lee HW. Expression of p21 (WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 2003;22(38):6023-6031.
44. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005;64(3):224-239.
45. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999;19(7):4798-4805.
46. Han JW, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW. Activation of p21 (WAF1/Cip1) transcription through SpI sites by histone deacetylase inhibitor apicidin: Involvement of protein kinase C. J Biol Chem 2001;276(45):42084-42090.
47. Ju R, Muller MT. Histone deacetylase inhibitors activate p21 (WAFI) expression via ATM. Cancer Res 2003;63(11):2891-2897.
48. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ralan RR. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 2003;100(7):4281-4286.
49. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 2002;277(29):25904-25913.
50. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem 2003;278(21):18980-18989.
51. Kanegae Y, Tavares AT, Izpisua Belrnonte JC, Verma IM. Role of Rel/NF-kappaB transcription factors during the out-growth of the vertebrate limb. Nature 1998;392(6676):611-614.
52. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H. Long-term androgen-ablation causes increased resistance to P13K/Akt pathway inhibition in prostate cancer cells. Prostate 2004;58(3):259-268.
53. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59(2):177-189.
54. Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 1999;18(22):3316-3323.